XENON PHARMACEUTICALS INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-345.9M | $-234.3M | $-182.4M | $-125.4M | $-78.9M | $-28.8M | $-41.6M | $-34.5M |
| Depreciation & Amortization | $2.5M | $2.6M | $2.1M | $1.4M | $906.0K | $644.0K | $429.0K | $586.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $53.7M | $50.7M | $32.4M | $20.4M | $10.0M | $5.7M | $2.9M | $2.6M |
| Net Cash from Operating Activities | $-279.1M | $-181.4M | $-151.1M | $-101.0M | $-69.5M | $-48.1M | $-4.7M | $-34.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $799.0K | $3.1M | $5.6M | $2.9M | $2.1M | $2.6M | $1.2M | $507.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $218.0M | $165.0M | $-111.4M | $-293.4M | $-246.8M | $-16.8M | $-66.2M | $-29.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $117.1M | $12.1M | $353.5M | $278.5M | $447.5M | $85.8M | $27.5M | $111.6M |
| Net Change in Cash | $56.5M | $-5.9M | $91.4M | $-118.4M | $130.7M | $20.3M | $-43.0M | $47.3M |
| Free Cash Flow | $-279.9M | $-184.5M | $-156.7M | $-103.9M | $-71.6M | $-50.8M | $-6.0M | $-35.2M |